These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 33986125)

  • 41. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
    Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
    Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
    Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
    Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
    Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
    Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
    Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
    Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
    Huber ML; Haynes L; Parker C; Iversen P
    J Natl Cancer Inst; 2012 Feb; 104(4):273-9. PubMed ID: 22232132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
    Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
    Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CTLA-4 antibody ipilimumab negatively affects CD4
    Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
    Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
    Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW
    Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
    Aamdal E; Inderberg EM; Ellingsen EB; Rasch W; Brunsvig PF; Aamdal S; Heintz KM; Vodák D; Nakken S; Hovig E; Nyakas M; Guren TK; Gaudernack G
    Front Immunol; 2021; 12():663865. PubMed ID: 34046035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T.
    Hawley JE; Pan S; Kandadi H; Chaimowitz MG; Sheikh N; Drake CG
    J Natl Cancer Inst; 2022 Feb; 114(2):314-317. PubMed ID: 34302463
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
    Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
    Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
    Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
    J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate cancer immunotherapy.
    May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW
    Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating immune responses after sipuleucel-T therapy.
    Strauss J; Madan RA; Figg WD
    Cancer Biol Ther; 2015; 16(8):1119-21. PubMed ID: 26054644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer.
    Thomsen LCV; Honoré A; Reisæter LAR; Almås B; Børretzen A; Helle SI; Førde K; Kristoffersen EK; Kaada SH; Melve GK; Haslerud TM; Biermann M; Bigalke I; Kvalheim G; Azeem W; Olsen JR; Gabriel B; Knappskog S; Halvorsen OJ; Akslen LA; Bahn D; Pantel K; Riethdorf S; Ragde H; Gjertsen BT; Øyan AM; Kalland KH; Beisland C
    Cancer Immunol Immunother; 2023 Jul; 72(7):2357-2373. PubMed ID: 36939854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.